. We challenge the proposal that FSH is required for hypogonadal bone loss. We suggest that the two mouse models used in the Sun et al. study have hormonal features-raised levels of luteinizing hormone (LH) and testosterone as a secondary consequence of FSH loss-that could explain the preservation of bone, without any need to invoke additional bone-specific actions of FSH.
LH stimulates ovarian theca cells to produce testosterone (Kumar, 2005) . This effect is especially pronounced in the absence of FSH signaling when LH levels are increased due to overlapping negative feedback pathways in the hypothalamus and pituitary. The increased LH levels in turn boost testosterone production by theca cells. Previous work in mice lacking FSHR showed that blood testosterone levels are increased up to 10-fold in immature and mature female mice (Balla et al., 2003; Danilovich et al., 2000; Abel et al., 2003) . Moreover, uterine hypertrophy and other defects in mice lacking either FSHR or FSHβ are likely due to increased testosterone that is of ovarian origin (Abel et al., 2003) . We argue that changes in the production of these sex steroids and not the loss of FSH signaling account for the observations by Sun et al. Unfortunately, Sun et al. did not report the concentration of serum LH or testosterone in their two mouse models.
We have shown that in the hpg hypogonadal mouse, marked bone loss is present in males (Sims et al., 2005 ). Sun and colleagues reported similar findings in female hpg mice in another recent study (Rajendren et al., 2006) . The hpg mouse is a naturally occurring model of hypogonadism caused by a mutation in the gene encoding gonadotropin-releasing hormone (GnRH) (Cattanach et al., 1977; Mason et al., 1986a) . These mice have postnatal deficiencies in FSH, LH, and gonadal sex steroid hormones. As a consequence, the reproductive system fails to mature, rendering hpg mice a valuable model of human idiopathic hypogonadotropic hypogonadism. The hpg mouse remains sensitive to testosterone or estradiol because hormone replacement reverses the deficits in mature somatic tissues (Singh et al., 1995; Spaliviero et al., 2004) . Importantly, the bone deficit in hpg mice is rectified by restoration of testosterone in males, or estradiol in females (Rajendren et al., 2006; Sims et al., 2005) 
